| References |
| 1 |
Chlorzoxazone was approved by FDA. The 2020 official website of the U.S. Food and Drug Administration.
|
| 2 |
Wild-type CYP102A1 as a biocatalyst: turnover of drugs usually metabolised by human liver enzymes. J Biol Inorg Chem. 2007 Mar;12(3):313-23.
|
| 3 |
The bacterial P450 BM3: a prototype for a biocatalyst with human P450 activities. Trends Biotechnol. 2007 Jul;25(7):289-98.
|
| 4 |
Prediction of human liver microsomal oxidations of 7-ethoxycoumarin and chlorzoxazone with kinetic parameters of recombinant cytochrome P-450 enzymes. Drug Metab Dispos. 1999 Nov;27(11):1274-80.
|
| 5 |
Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metab Rev. 2002 Feb-May;34(1-2):83-448.
|
| 6 |
Robustness of chlorzoxazone as an in vivo measure of cytochrome P450 2E1 activity Br J Clin Pharmacol. 2004 Aug;58(2):190-200. doi: 10.1111/j.1365-2125.2004.02132.x.
|
| 7 |
Amalgamation of in-silico, in-vitro and in-vivo approach to establish glabridin as a potential CYP2E1 inhibitor. Xenobiotica. 2021 Jun;51(6):625-635. doi: 10.1080/00498254.2021.1883769.
|
| 8 |
Generation and Characterization of CYP2E1-Overexpressing HepG2 Cells to Study the Role of CYP2E1 in Hepatic Hypoxia-Reoxygenation Injury. Int J Mol Sci. 2023 May 1;24(9):8121. doi: 10.3390/ijms24098121.
|
